Accredited E-Newsletter Series

Clinical Trial Tracker: An Update on Promising Phase 2 and 3 Clinical Trials in Pancreatic Cancer
Clinical Trial Tracker: An Update on Promising Phase 2 and 3 Clinical Trials in Pancreatic Cancer
CME, CPE
J. Randolph Hecht, MD
Release Date: October 24, 2018
Expiration Date: October 24, 2019

Despite recent progress involving adjuvant and neoadjuvant approaches, treatment options for pancreatic ductal adenocarcinoma (PDA) remain unsatisfying, especially in the salvage setting of locally advanced and metastatic disease. Immune therapies have been successful in a number of other tumor types, but pancreatic cancer has been largely refractory to these otherwise exciting approaches. Fortunately, many novel compounds are in development that may well improve long-term outcomes of this challenging malignancy.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.
View Only, CE ExpiredView Only, No Credit
 
The Current State of Personalized Medicine: Biomarkers in Pancreatic Cancer
The Current State of Personalized Medicine: Biomarkers in Pancreatic Cancer
CME, CPE
Eileen M. O’Reilly, MD
Release Date: June 06, 2018
Expiration Date: June 06, 2019

The mainstay of pancreatic cancer therapy—cytotoxic regimens—have only minimally improved outcomes for this often-lethal malignancy, and targeted therapies have, to date, had only limited efficacy. This poor prognosis is a result of the late diagnosis of the disease, its early metastatic dissemination, the tumor’s immune privilege, the lack of robust drug targets in the tumor, and this cancer’s intrinsic resistance to systemic and immune therapies, in part owing to its abundant stromal content that creates a physical barrier to drug delivery. With better understanding of the genetic landscape of pancreas cancer, targeted approaches are emerging that will benefit biomarker-selected patients. New ways in which to enhance the microenvironment—both immunologically and to facilitate drug delivery—are also expected to result in better outcomes for patients.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.
View Only, CE ExpiredView Only, No Credit
 
Cutting-Edge Treatment Strategies in Metastatic Pancreatic Cancer: The Clinical Trial Option
Cutting-Edge Treatment Strategies in Metastatic Pancreatic Cancer: The Clinical Trial Option
CME, CPE
Philip A. Philip, MD, PhD, FRCP
Release Date: November 09, 2016
Expiration Date: November 09, 2017
This text-based e-newsletter activity will summarize why participation in clinical trials is one of the recommended first-line treatments for patients with metastatic, unresectable pancreatic cancer, and will identify patient types that are most likely to benefit from participation in a clinical trial. Emphasis will be placed on resources oncology clinicians can utilize to locate the most appropriate clinical trials for their individual patients with pancreatic cancer.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Incyte Corporation
View Only, CE ExpiredView Only, No Credit
 
Expert Insight into the 2016 ASCO Updates for Metastatic Pancreatic Cancer
Expert Insight into the 2016 ASCO Updates for Metastatic Pancreatic Cancer
CME, CPE
Alok A. Khorana, MD
Release Date: September 16, 2016
Expiration Date: September 16, 2017
In this activity, Dr. Khorana, Professor of Medicine and Director of the Gastrointestinal Malignancies Program at the Cleveland Clinic, provides an overview of the recently released guidelines for the management of potentially curable, locally advanced/unresectable, and metastatic pancreatic cancer to assist health care providers in their application of clinical recommendations to practice.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Incyte Corporation
View Only, CE ExpiredView Only, No Credit
 
Tailoring Treatment Strategies in Pancreatic Cancer: Prognostic Factors that Matter
Tailoring Treatment Strategies in Pancreatic Cancer: Prognostic Factors that Matter
CME, CPE
Eileen M. O’Reilly, MD
Release Date: May 16, 2016
Expiration Date: May 16, 2017
This activity will describe the use of molecular biomarkers to tailor personalized treatment strategies for patients with pancreatic cancer. Dr. Eileen M. O’Reilly, Medical Oncologist and Associate Director for Clinical Research at the David M. Rubenstein Center for Pancreatic Cancer Research, provides insight into the future use of BRCA mutations to guide treatment with platinum-based therapies, in addition to other potential biomarkers, including C-reactive protein (CRP), hyaluronan (HA), and the use of immunogenic subgrouping to maximize outcomes from immune therapies.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Incyte Corporation
View Only, CE ExpiredView Only, No Credit
 
Fast Facts in Palliative Care: A Focus on Pancreatic Cancer
Fast Facts in Palliative Care: A Focus on Pancreatic Cancer
CME, CPE
Nina N. Grenon, DNP, AGCNP-BC, AOCN
Release Date: March 21, 2016
Expiration Date: March 21, 2017
This text-based e-newsletter activity will summarize the disease- and treatment-related symptoms of pancreatic cancer that have a negative impact on patients’ quality of life, and the role of palliative care in improving QOL. This activity will include a practical guide for communicating with your patients concerning palliative care and its integration as a key therapeutic strategy across the continuum of disease.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Incyte Corporation
View Only, CE ExpiredView Only, No Credit
 

MediCom Worldwide, Inc. would like to thank Celgene Corporation for their educational support of PartnersinPancreaticCancer.com.

©2020 MediCom Worldwide, Inc. All rights reserved